Floatz logo

RIFALDAZINE

Synovial Sarcoma

Epizyme, Inc.Small moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Synovial Sarcoma cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2BB
Cyclophosphamide
Zelluna Immunotherapy AS
Phase 2BB
Pembrolizumab
Valo Therapeutics Oy
Phase 2B
Cixutumumab
National Cancer Institute (NCI)
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B

View all 36 →

Same molecule, other indications

RIFALDAZINE is also rated in:

methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
71 / 100
View asset →
cystic fibrosisDormant
BB
Indicative ·
65 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →